e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Physiology, obesity and the downstream effects of OSA
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients
R. Plywaczewski, L. Jonczak, P. Bielen, D. Gorecka, P. Sliwinski (Warsaw, Poland)
Source:
Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA
Session:
Physiology, obesity and the downstream effects of OSA
Session type:
Poster Discussion
Number:
3193
Disease area:
Sleep and breathing disorders
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Plywaczewski, L. Jonczak, P. Bielen, D. Gorecka, P. Sliwinski (Warsaw, Poland). Cardiovascular diseases are responsible for increased plasma NT-proBNP level in obstructive sleep apnoea (OSA) patients. Eur Respir J 2012; 40: Suppl. 56, 3193
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
Panel discussion on acute decompensated pulmonary hypertension
Related content which might interest you:
Relationship between plasma NT-proBNP level and cardiovascular complications in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease
Year: 2010
Relationship between NT-proBNP plasma level and nocturia in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2007 - Systemic effects of obstructive sleep apnoea
Year: 2007
Relationship between NT-proBNP level, echocardiographic parameters and cardiovascular diseases in patients with obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Physiology, obesity and the downstream effects of OSA
Year: 2012
BNP or VEGF levels do not predict disease severity in obstructive sleep apnoea syndrome (OSAS)
Source: Eur Respir J 2005; 26: Suppl. 49, 40s
Year: 2005
Comparison of plasma NT-proBNP level in overlap syndrome (obstructive sleep apnoea + chronic obstructive pulmonary disease) and obstructive sleep apnoea (OSA)
Source: Annual Congress 2008 - Control of breathing and respiratory disorders during sleep
Year: 2008
Relations between cystatin C plasma concentration and cardiovascular complications in patients with obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I
Year: 2012
Physical activity in obstructive sleep apnea (OSA) patients with high cardiovascular risk
Source: Annual Congress 2010 - Obesity: positive effects of bariatric surgery and exercise
Year: 2010
C-reactive protein (CRP) and prevalence of cardiovascular diseases in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2007 - Sleep apnoea in cardiorespiratory disorders
Year: 2007
Angio-inhibitory activity and decreased leptin level in sera from obstructive sleep apnea syndrome (OSAS) patients
Source: Eur Respir J 2001; 18: Suppl. 33, 334s
Year: 2001
Association between metabolic disturbances and inflammatory markers in obstructive sleep apnea (OSAS) patients
Source: Annual Congress 2008 - Metabolic syndrome and systemic inflammation in obstructive sleep apnoea
Year: 2008
NT-proBNP in obstructive sleep apnoea (OSA)
Source: Eur Respir J 2006; 28: Suppl. 50, 415s
Year: 2006
The risk of future cardiovascular diseases in the patients with OSAS is dependently or independently associated with obstructive sleep apnoea
Source: Eur Respir J 2001; 17: 573-574
Year: 2001
Plasma adiponectin levels and hypoxic stress in patients with obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2004 - Systemic and metabolic effects from OSA
Year: 2004
Prevalence of stroke in obstructive sleep apnoea (OSA) patients
Source: Eur Respir J 2007; 30: Suppl. 51, 331s
Year: 2007
Prevalence of cardiorespiratory disease increase with increasing severity of obstructive sleep apnoea (OSA)
Source: Eur Respir J 2002; 20: Suppl. 38, 322s
Year: 2002
Impaired glucose tolerance and other cardiovascular risk factors in patients with obstructive sleep apnea syndrome (OSAS)
Source: Annual Congress 2009 - Systemic consequences of sleep-disordered breathing
Year: 2009
C-reactive protein (CRP) levels in obstructive sleep apnea (OSA) patients and relation to severity of OSA
Source: Annual Congress 2011 - Cardiometabolic and neurocognitive changes in obstructive sleep apnoea
Year: 2011
Influence of body weight on plasma NT-proBNP in obstructive sleep apnoea (OSA) patients
Source: Annual Congress 2007 - Cardiovascular and respiratory control in obstructive sleep apnoea
Year: 2007
Correlations between cardiovascular diseases and diabetes in obstructive sleep apnoea (OSA)
Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA I
Year: 2012
Association between obstructive sleep apnoea (OSA) severity and metabolic disturbances
Source: International Congress 2017 – Obstructive and central sleep apnoea: consequences and comorbidities
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept